{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:30:52Z","timestamp":1786681852866,"version":"build-2736575974"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease worldwide. Type 2 diabetes (T2D) and obesity are major risk factors for its development and progression. Body mass index (BMI), although widely used in clinical practice, fails to adequately reflect individual differences in body composition and fat distribution. This study evaluated the association of adiposity and reduced muscle mass \u2013 measured by dual-energy X-ray absorptiometry (DXA) \u2013 with hepatic steatosis severity in patients with MASLD and T2D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Consecutive patients with MASLD and T2D were recruited at a tertiary hepatology centre. Body composition was assessed by DXA. Adiposity was defined using fat mass percentage, with values &amp;gt;25% in men and &amp;gt;35% in women indicating obesity. Muscle mass was assessed using the appendicular lean mass\/height\n                      <jats:sup>2<\/jats:sup>\n                      (ALM\/height\u00b2) index, with pathological values defined as &amp;lt;7.0 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      in men and &amp;lt;5.5 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      in women. Hepatic steatosis and fibrosis were evaluated by controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), respectively. Statistical analyses included Spearman\u2019s rank correlation, Chi Square test, logistic regression, and receiver operating characteristic (ROC) curve analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ninety-seven patients (median age 61 years) were enrolled. DXA identified a pathological fat mass percentage in 97.9% of patients, whereas 46.4% met the BMI-based criteria for obesity. At multivariate analysis, fat mass percentage and pathological ALM\/height\n                      <jats:sup>2<\/jats:sup>\n                      were independently related with severe hepatic steatosis (CAP \u2265280 dB\/m; OR 1.100,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.011; OR 0.292,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.013, respectively). ROC curve analysis identified specific cut-offs for fat mass percentage (38.65%, area under the curve [AUC] of 0.636) and ALM\/height\n                      <jats:sup>2<\/jats:sup>\n                      index (6.7 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , AUC of 0.611) for detecting severe liver steatosis. A model combining both cut-offs yielded an AUC of 0.715 (95% C.I. 0.610 \u2013 0.820,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with MASLD and T2D, DXA-derived body composition measures may complement conventional anthropometric assessment and help identify individuals with severe hepatic steatosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1901793","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:22:50Z","timestamp":1786681370000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Body composition assessment for risk stratification of hepatic steatosis in patients with type 2 diabetes and MASLD undergoing osteoporosis screening"],"prefix":"10.3389","volume":"17","author":[{"given":"Clelia","family":"Asero","sequence":"first","affiliation":[{"name":"Division of Medicine and Hepatology, University Hospital of Messina","place":["Messina, Italy"]},{"name":"Department of Clinical and Experimental Medicine, University of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Oliveri","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina","place":["Messina, Italy"]},{"name":"Geriatric Unit, University Hospital of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Stella","family":"Franz\u00e8","sequence":"additional","affiliation":[{"name":"Division of Medicine and Hepatology, University Hospital of Messina","place":["Messina, Italy"]},{"name":"Department of Clinical and Experimental Medicine, University of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Basile","sequence":"additional","affiliation":[{"name":"Geriatric Unit, University Hospital of Messina","place":["Messina, Italy"]},{"name":"Department of Biomedical and Dental Science and Morphofunctional Imaging, University of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Catalano","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina","place":["Messina, Italy"]},{"name":"Geriatric Unit, University Hospital of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cacciola","sequence":"additional","affiliation":[{"name":"Division of Medicine and Hepatology, University Hospital of Messina","place":["Messina, Italy"]},{"name":"Department of Clinical and Experimental Medicine, University of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease in adults: A review","volume":"335","author":"Tilg","year":"2026","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12082858","article-title":"High prevalence of severe hepatic fibrosis in type 2 diabetic outpatients screened for non-alcoholic fatty liver disease","volume":"12","author":"Asero","year":"2023","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s13679-025-00637-9","article-title":"Metabolically healthy obesity and metabolic dysfunction-associated steatotic liver disease (MASLD): Navigating the controversies in disease development and progression","volume":"14","author":"Koliaki","year":"2025","journal-title":"Curr Obes Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/dom.70659","article-title":"Obesity and metabolic dysfunction\u2010associated steatotic liver disease (MASLD): A literature review on pathophysiology and treatment","volume":"28","author":"Romanos","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Pich\u00e9","year":"2020","journal-title":"Circ Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i20.105346","article-title":"Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass","volume":"31","author":"Isakov","year":"2025","journal-title":"World J Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/jhn.12278","article-title":"Body composition and morphological assessment of nutritional status in adults: a review of anthropometric variables","author":"Madden","year":"2014","journal-title":"J Hum Nutr Diet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2026.101283","article-title":"Methodological standards for body composition assessment-an expert-endorsed guide for research and clinical applications: bioimpedance, dual-energy X-ray absorptiometry, computerized tomography, and ultrasound methods","volume":"123","author":"Prado","year":"2026","journal-title":"Am J Clin Nutr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13679-024-00593-w","article-title":"Updates on methods for body composition analysis: Implications for clinical practice","volume":"14","author":"Thomas","year":"2025","journal-title":"Curr Obes Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3548284","article-title":"Assessment of body composition in health and disease using bioelectrical impedance analysis (BIA) and dual energy X-ray absorptiometry (DXA): A critical overview","volume":"2019","author":"Marra","year":"2019","journal-title":"Contrast Media Mol Imaging"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-026-02848-w","article-title":"Trabecular bone score enhances fracture risk stratification in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus","author":"Asero","year":"2026","journal-title":"J Endocrinol Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL clinical practice guidelines: Management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114521002579","article-title":"Tracking changes in body composition: Comparison of methods and influence of pre-assessment standardisation","volume":"127","author":"Tinsley","year":"2022","journal-title":"Br J Nutr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/nu17142374","article-title":"The visceral adiposity index and its usefulness in the prediction of cardiometabolic disorders","volume":"17","author":"Jakubiak","year":"2025","journal-title":"Nutrients"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1017\/S1368980012002996","article-title":"Convergent validity of the international physical activity questionnaire (IPAQ): Meta-analysis","volume":"16","author":"Kim","year":"2013","journal-title":"Public Health Nutr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fresc.2021.712977","article-title":"DXA-derived adiposity and lean indices for management of cardiometabolic and musculoskeletal frailty: Data interpretation tricks and reporting tips","volume":"2","author":"Minetto","year":"2021","journal-title":"Front Rehabil Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s13679-024-00584-x","article-title":"Correction: Strengths and limitations of BMI in the diagnosis of obesity: What is the path forward","volume":"13","author":"Sweatt","year":"2024","journal-title":"Curr Obes Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2006.83","article-title":"Waist circumference correlates with metabolic syndrome indicators better than percentage fat","volume":"14","author":"Shen","year":"2006","journal-title":"Obesity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2017.289","article-title":"Comparison of regional fat measurements by dual-energy X-ray absorptiometry and conventional anthropometry and their association with markers of diabetes and cardiovascular disease risk","volume":"42","author":"Vasan","year":"2018","journal-title":"Int J Obes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/diseases14050173","article-title":"Lean metabolic-dysfunction-associated steatotic liver disease (MASLD): Pathophysiology, diagnostic challenges, clinical outcomes, and management","volume":"14","author":"Albusta","year":"2026","journal-title":"Diseases"},{"key":"B29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s13098-025-02015-w","article-title":"Lean type 2 diabetes: The overlooked epidemic reshaping global health","volume":"17","author":"Singh","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1490277","article-title":"Body composition differences in patients with metabolic dysfunction-associated steatotic liver disease","volume":"11","author":"Bernal-Contreras","year":"2024","journal-title":"Front Nutr"},{"key":"B31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40520-024-02694-x","article-title":"Calf circumference as a surrogate indicator for detecting low muscle mass in hospitalized geriatric patients","volume":"36","author":"Kiss","year":"2024","journal-title":"Aging Clin Exp Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.94766","article-title":"Association between metabolic dysfunction-associated steatotic liver disease and sarcopenia: A systematic review and meta-analysis","volume":"17","author":"Hussaini","year":"2025","journal-title":"Cureus"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112924","article-title":"GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review","volume":"229","author":"Pantazopoulos","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"B34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13668-025-00649-w","article-title":"Impact of GLP-1 receptor agonist therapy in patients high risk for sarcopenia","volume":"14","author":"Memel","year":"2025","journal-title":"Curr Nutr Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70643","article-title":"Effects of GLP-1 receptor agonists on muscle mass, strength, and quality in MASLD: A systematic review","volume":"46","author":"Iorra","year":"2026","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0000000000001130","article-title":"Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary","volume":"28","author":"Chavez","year":"2025","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/nu16111586","article-title":"The link between abdominal obesity indices and the progression of liver fibrosis: Insights from a population-based study","volume":"16","author":"Juli\u00e1n","year":"2024","journal-title":"Nutrients"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1464_24","article-title":"Waist circumference as a predictor for severity of liver fibrosis in non-alcoholic fatty liver disease patients","volume":"14","author":"Suri","year":"2025","journal-title":"J Fam Med Prim Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13098-023-01156-0","article-title":"Waist circumference is independently associated with liver steatosis and fibrosis in LMNA-related and unrelated familial partial lipodystrophy women","volume":"15","author":"Viola","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103405","article-title":"Association between visceral adiposity and the prediction of hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"14","author":"Bende","year":"2025","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187066","article-title":"The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter","volume":"12","author":"Lee","year":"2017","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.777","article-title":"Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes","volume":"10","author":"Mansour","year":"2024","journal-title":"Obes Sci Pract"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms","volume":"83","author":"Steinberg","year":"2025","journal-title":"J Hepatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12876-024-03192-0","article-title":"The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations","volume":"24","author":"Feng","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2024.07.006","article-title":"The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis","volume":"43","author":"Li","year":"2024","journal-title":"Clin Nutr Edinb Scotl"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17930","article-title":"Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000711","article-title":"Skeletal muscle and MASLD: Mechanistic and clinical insights","volume":"9","author":"Marjot","year":"2025","journal-title":"Hepatol Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v16.i6.871","article-title":"Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both","volume":"16","author":"Wong","year":"2024","journal-title":"World J Hepatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15041661","article-title":"Metabolic dysfunction-associated steatotic liver disease and sarcopenia: Review of literature","volume":"15","author":"Nishikawa","year":"2026","journal-title":"J Clin Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.019","article-title":"Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis","volume":"66","author":"Koo","year":"2017","journal-title":"J Hepatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s10238-025-01865-y","article-title":"Sarcopenic visceral obesity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"25","author":"Elsabaawy","year":"2025","journal-title":"Clin Exp Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12986-025-01000-4","article-title":"Prevalence and risk of metabolic dysfunction-associated steatotic liver disease in patients with sarcopenic obesity: a systematic review and meta-analysis","volume":"22","author":"Wang","year":"2025","journal-title":"Nutr Metab"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-08844-z","article-title":"Clinical relevancies of sarcopenic obesity in patients with metabolic dysfunction-associated fatty liver disease (MASLD)","volume":"70","author":"Chien","year":"2025","journal-title":"Dig Dis Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1246157","article-title":"The relationship between skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease subtypes in middle-aged and elderly population: a single-center retrospective study","volume":"10","author":"Xing","year":"2023","journal-title":"Front Nutr"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1901793\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:22:51Z","timestamp":1786681371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1901793\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":54,"alternative-id":["10.3389\/fendo.2026.1901793"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1901793","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1901793"}}